Company believes it will create an in vitro-in vivo bridge for pharma to reduce attrition of drug candidates.

Caliper Life Sciences unveiled Caliper Discovery Alliances & Services (CDAS), the services organization born out of the integration of NovaScreen Biosciences an in vitro discovery service provider and Xenogen Biosciences an in vivo discovery service provider.

“We are excited to now be one of the few providers focused on offering services that span in vitro and in vivo experimentation,” says David Manyak, executive vp of discovery services of Caliper and head of CDAS.

Caliper acquired NovaScreen in October 2005 and Xenogen in August 2006. The company says that its strategy is to provide its customers with the tools for building an in vitro-in vivo bridge, or an I-I Bridge, to address the growing pressure on the pharmaceutical industry to find new, effective drugs while minimizing the risk of adverse effects of those drugs. “By building the I-I Bridge in the context of a services offering, we are providing scientists a way to explore new approaches to drug discovery with minimal resource commitment,” remarks Kevin Hrusovsky, president and CEO of Caliper.

Caliper Discovery Alliances & Services offers more than 700 in vitro assay types, profiling assays, side effect and ADME-tox panels, and cellular models for immunology, oncology, and other fields, reports Caliper. In vivo offerings include more than 85 pharmacological assays that measure over 400 different parameters, adds the company.

Previous articleSeattle Genetics Enhances Cancer Program with Two Transactions
Next articleGenentech Procures Amphora Oncology Program